At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 2,505 enrolled
Drug / intervention
unfractionated heparindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions
In Brief
A Phase 4 clinical trial evaluating unfractionated heparin for Coronary Artery Disease. Completed, enrolled 2,505 participants across 3 sites.
Detailed Summary
The aim of this trial is to evaluate whether a reduction in the heparin dose from 140 to 100 U/kg is associated with a better net clinical outcome in patients undergoing PCI after pretreatment with 600mg clopidogrel
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedAug 2008
Primary CompletionMar 2010
Study CompletionMar 2011
TodayJul 2026
First PostedAug 14, 2008
Enrollment StartAug 1, 2008
Primary CompletionMar 1, 2010
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.9 years ago
Interventions
unfractionated heparindrug
bolus of 100 U/kg of unfractionated heparin